Introduction
============

Solid tumors such as colorectal cancer (CRC) consist of a heterogeneous population of cancer cells. Among these cell populations, cancer stem cells (CSCs) are a limited population that possess self-renewing ability as well as the ability to initiate a heterogeneous tumor in serially transplanted immunodeficient mice. Due to this ability, CSCs are thought to be located at the top of the hierarchy of tumor differentiation ([@b1-or-40-02-0693]--[@b3-or-40-02-0693]). CSCs are in a quiescent state and have mechanisms to reduce reactive oxidative stress, leading to resistance to chemotherapy or radiotherapy. Furthermore, CSCs change their biological characteristics depending on their microenvironments to develop distant metastasis. CSCs are therefore thought to be responsible for cancer recurrence and metastasis ([@b4-or-40-02-0693]--[@b7-or-40-02-0693]). Based on these concepts, CSCs are considered to be the most important treatment target to overcome cancers.

Surface markers of CSCs have been explored in the last decade ([@b8-or-40-02-0693]--[@b10-or-40-02-0693]). The transmembrane glycoprotein CD44, a receptor of hyaluronic acid, is a CSC marker in various cancers ([@b8-or-40-02-0693],[@b11-or-40-02-0693]). Dalerba *et al* revealed that the EpCAM^high^/CD44^+^ population of CRC cells has the ability to produce a xenograft tumor in immunodeficient mice, suggesting that these cells may be the CSC population of CRC ([@b12-or-40-02-0693]). However, CSC selection according to the expression of CD44 and EpCAM molecules was not sufficient to identify genuine colorectal CSCs since tumor cells with other markers, such as CD133 or ALDH1, also produce xenograft tumors regardless of CD44 expression ([@b13-or-40-02-0693],[@b14-or-40-02-0693]). Therefore, additional markers are required to more precisely identify colorectal CSCs.

Recently, Sada *et al* reported that two molecularly distinct stem cell populations reside in the interfollicular epidermis of adult skin ([@b15-or-40-02-0693]). Although these two stem cell populations contribute to maintenance of homeostasis in their territories, they participate in injury repair in both territories. Pathologically distinct populations of CSCs have never been identified in tumors. Since tumors consist of heterogeneous populations, pathologically distinct populations of CSCs may reside in tumors.

E-cadherin is a member of the cadherin superfamily and is preferentially expressed in epithelial cells. E-cadherin mediates cell-cell adhesion through its extracellular domain in the presence of calcium ions. In the cytoplasm, E-cadherin is associated with α-, β- and p120-catenin, which in turn bind to actin filaments. E-cadherin is not only important for regulation of cell-cell contact, but it also plays a role in regulation of signal transduction pathways via actin filaments. Recently, E-cadherin was reported to be an essential molecule for the self-renewing process of embryonic stem cells ([@b16-or-40-02-0693]). In this previous study, it was demonstrated that E-cadherin regulated human embryonic stem cell self-renewal through interaction with Rap1. E-cadherin was also revealed to suppress cancer cell proliferation in CRC ([@b17-or-40-02-0693]). N-cadherin is also important for maintenance of stemness of hematopoietic stem cells. Although cadherins are important for maintenance of stem cell properties and cell proliferation, whether E-cadherin regulates stemness and cell proliferation in colorectal CSCs is unclear.

We hypothesized that E-cadherin is essential for the maintenance of properties of colorectal CSCs. We examined the impact of E-cadherin expression on colorectal CSCs using human clinical samples. EpCAM^high^/CD44^+^ CSCs contained both E-cadherin-positive (EC^+^) and -negative (EC^−^) cells. Surprisingly, EC^+^ cells exhibited higher tumor growth potential than EC^−^ cells *in vivo*. Upregulation of NANOG, which is a key molecule for induction of the proliferation of embryonic stem cells, may contribute to the higher tumor growth potential of EC^+^ colorectal CSCs.

Materials and methods
=====================

### Patients and tumor tissues

From July 2009 to December 2013, surgical specimens of CRC patients were collected for this study after written informed consent was obtained from patients at Kyushu University Hospital. The study protocol was approved by the Institutional Review Board of Kyushu University Hospital in 2009. In total, 18 samples (from 9 males and 9 females, mean age 64.6 years old) were used for this study and all samples were obtained from the primary site of CRC. As shown in [Table I](#tI-or-40-02-0693){ref-type="table"}, most cases had well or moderately differentiated adenocarcinomas.

### Tumor cell isolation

CRC tissue and normal colon tissue from surgical specimens were mechanically minced into small fragments using a scalpel and scissors in serum-free cell culture medium (RPMI-1640; Wako Pure Chemicals Industries, Ltd., Osaka, Japan). The fragments were enzymatically digested by agitating in HEPES (Wako Pure Chemicals Industries, Ltd.) supplemented with 200 U/ml collagenase type III (Merck Millipore, Darmstadt, Germany) and 100 U/ml DNase I (Takara Bio Inc., Shiga, Japan) for 2 h at 37°C. The cells were then filtered through 100-µm and 40-µm nylon meshes, and the remaining cells were resuspended in serum-free medium.

### Flow cytometry and cell-sorting experiments

Isolated cancer cells from surgical specimens were resuspended in FCM buffer (HBSS containing 2% FBS supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 50 µg/ml ceftazidime, 0.25 µg/ml amphotericin-B, 1 mM EDTA, and 1 mM sodium pyruvate) for incubation with fluorescein-labeled antibodies. PE-conjugated anti-CD44 antibody (1:50; cat. no. 561858; BD Biosciences, San Jose, CA, USA) and APC-conjugated anti-EpCAM antibody (1:50; cat. no. 324207; BioLegend, Inc., San Diego, CA, USA) were added, and the cells were incubated for 1 h on ice in the dark. After incubation, the cells were washed twice with PBS and then resuspended in FCM buffer. Flow cytometry was performed using FACSAria II (BD Biosciences, Franklin Lakes, NJ, USA). The viable mononuclear single cell population was gated by forward scatter and propidium iodide staining, and was then sorted with CD44, EpCAM and E-cadherin.

### Immunodeficient mice and xenotransplantation

NOD/SCID mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). They were housed in groups of 1--4 per cage in a light-controlled room (lights on 7 a.m. to 7 p.m.) at a room temperature of 24±1°C with food and water *ad libitum*. Forty-six mice (27 males and 19 females) were used. The indicated numbers of sorted tumor cells were resuspended in 200 µl BD Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) plus medium. The cell-Matrigel suspension was subcutaneously injected into the opposite flanks of 6-to 8-week-old NOD/SCID mice using a 23-gauge syringe. Tumor formation was observed for up to 6 months. The mice were sacrificed under anesthesia when the tumor size reached a maximum diameter of 20 mm. Xenograft tumors were then isolated from the mice and further analyzed using the same analysis techniques as those used for human colorectal samples or were fixed in 10% formalin solution. All animal experiments were performed in accordance with the Institutional Animal Welfare Guidelines of Kyushu University.

### Immunohistochemistry and immunofluorescence

Formalin-fixed xenograft tumors were cut into 5 µm-thick serial sections and immunohistochemical studies were performed with avidin-biotin-peroxidase complex kits (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer\'s instructions. The sections were then counterstained with hematoxylin. For immunofluorescence analysis, the slides were counterstained with DAPI and mounted. The primary antibodies used in this study were: Anti-E-cadherin (1:50; cat. no. sc-31021; Santa Cruz Biotechnology, Inc., Santa Cruz, Dallas, TX, USA), anti-CD44 (1:100; cat. no. 550538; BD Biosciences, San Jose, CA, USA), and anti-NANOG (1:100; cat. no. 4903; Cell Signaling Technology, Danvers, MA, USA).

### mRNA isolation and cDNA array

Total RNA was isolated from both EC^+^ cells and EC^−^ cells, using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc., Carlsbad, CA, USA) and was purified using the SV Total RNA Isolation System (Promega Corp., Madison, WI, USA), according to the manufacturer\'s instructions. The quality and quantity of the RNA samples obtained were verified using the Experion System (Bio-Rad Laboratories, Hercules, CA, USA) and an ND-1000 Spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc., Wilmington, DE, USA). The cRNA was amplified, labeled, and hybridized to a 60K Agilent 60-mer oligomicroarray according to the manufacturer\'s instructions. All hybridized microarray slides were scanned using an Agilent scanner (Agilent Technologies, Santa Clara, CA, USA). Relative hybridization intensities and background hybridization values were calculated using Agilent Feature Extraction Software (version 9.5.1.1). Raw signal intensities and flags for each probe were calculated from hybridization intensities (gProcessedSignal), and spot information (gIsSaturated) according to the procedures recommended by Agilent. The raw signal intensities of two samples were log~2~-transformed and normalized using a quantile algorithm with the 'preprocessCore' library package ([@b18-or-40-02-0693]) on Bioconductor software ([@b19-or-40-02-0693]). We selected probes that called a 'P' flag in both samples. To identify upregulated or downregulated genes, we calculated Z-scores ([@b20-or-40-02-0693]) and ratios (non-log scaled fold-change) from the normalized signal intensities of each probe for comparison between the control and experimental samples. We then established the following criteria for regulated genes: (upregulated genes) Z-score ≥2.0 or ratio ≥1.5-fold, (downregulated genes) Z-score ≤-2.0 or ratio ≤0.66.

### RNA interference for NANOG

Pre-designed *NANOG* siRNA was purchased from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). HCT116 cells were seeded in 35-mm dishes and transfected with control siRNA or *NANOG* siRNA using Lipofectamine 3000 according to the manufacturer\'s instructions (Thermo Fisher Scientific, Inc.). Ninety-six hours after transfection, the cells were collected and analyzed for *NANOG* mRNA expression with RT-qPCR and NANOG protein with an immunofluorescence study. For the cell proliferation assay, 1×10^3^ cells were seeded in 35-mm dishes 72 h after transfection, and then the number of viable cells was counted on days 1--5.

### RT-PCR and quantitative RT-PCR

Ninety-six hours after transfection, total RNA was extracted from the siRNA-transfected cells using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.), and 2 µg total RNA was used for first-strand cDNA synthesis using SuperScript^™^ IV VILO^™^ Master Mix (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer\'s instructions. RT-PCR was performed using TaKaRa Ex Taq^®^ (Takara Bio Inc.) and the Gene Amp PCR System 9,700 (Thermo Fisher Scientific, Inc.) at the following cycling conditions: 29 cycles of 30 sec at 94°C, 30 sec at 60°C and 60 sec at 72°C. Quantitative RT-PCR was performed using SYBR^®^ Premix Ex Taq™ II (Takara Bio Inc.) and StepOnePlus Real-Time PCR Systems (Thermo Fisher Scientific, Inc.). PCR was performed in triplicate.

Results are expressed as the NANOG copy number normalized to 10^4^ GAPDH. Gene specific primers used in this study were: NANOG forward, 5′-TGCAGAGAAGAGTGTCGCAA-3′ and reverse, 5′-CAGGTCTTCACCTGTTTGTAGC-3′; NANOG (qPCR) forward, 5′-GGTGTGACGCAGAAGGCCTCA-3′ and reverse, 5′-CCCAGTCGGGTTCACCAGGCA-3′; cyclin D1 forward, 5′-AGCTCCTGTGCTGCGAAGTGGAAAC-3′ and reverse, 5′-AGTGTTCAATGAAATCGTGCGGGGT-3′; cyclin A forward, 5′-CCTGCTCGTCACTTGGGATG-3′ and reverse, 5′-ACTGTAGCCAGCACAACTCC-3′; cyclin B1 forward, 5′-GCCTGCAAATGCCTGGTTTAT-3′ and reverse, 5′-GCCACAGCCTTGGCTAAATC-3′; cyclin E forward, 5′-TGGCGTTTAAGTCCCCTGAC-3′ and reverse, 5′-TCAGTTTTGAGCTCCCCGTC-3′; p21 forward, 5′-AGTACCCTCTCAGCTCCAGG-3′ and reverse, 5′-TGTCTGACTCCTTGT-3′ p27 forward, 5′-TGTCAAACGTGCGAGTGTCT-3′ and reverse, 5′-TGTCCTCAGAGTTAGCCGGA-3′; GAPDH forward, 5′-ACCCAGAAGACTGTGGATGG-3′ and reverse, 5′-TCTAGACGGCAGGTCAGGTC-3′.

### Statistical analysis

Results are expressed as the mean ± SE unless otherwise stated. Student\'s t-test was used to evaluate statistical significance. Values of P\<0.05 were considered to indicate a statistically significant difference.

Results
=======

### The EpCAM^high^/CD44^+^ population in CRC has tumor-initiating potential in immunodeficient mice

We examined surgically resected colorectal tumors from 18 patients ([Table I](#tI-or-40-02-0693){ref-type="table"}). Fifteen patients had clinical stage II or III disease, and two cases had clinical stage IV disease. Pathologically, most patients had well or moderately differentiated adenocarcinomas. We isolated the cancer cells enzymatically and sorted cells using anti-CD44 and anti-EpCAM antibodies as previously reported ([@b12-or-40-02-0693]). Fluorescence-activated cell sorting analysis indicated that colorectal tumors contained both an EpCAM^high^/CD44^+^ population and an EpCAM^positive^/CD44^−^ population of cells ([Fig. 1A](#f1-or-40-02-0693){ref-type="fig"}). To confirm that the EpCAM^high^/CD44^+^ population had tumorigenic potential *in vivo*, we transplanted 4×10^3^ EpCAM^high^/CD44^+^ cells or 1×10^4^ EpCAM^positive^/CD44^−^ cells subcutaneously into NOD/SCID mice. As shown in [Fig. 1B](#f1-or-40-02-0693){ref-type="fig"}, EpCAM^high^/CD44^+^ cells produced tumors (n=3, patients \#6-8), but no tumor was observed in mice in which EpCAM^positive^/CD44^−^ cells had been transplanted (n=3, patients \#6-8). This result revealed that EpCAM^high^/CD44^+^ CRC cells have tumorigenic potential *in vivo*.

Next, we investigated CD44 expression in the xenograft tumors by flow cytometric analysis to examine whether the EpCAM^high^/CD44^+^ population had the ability to self-renew and reconstitute a heterogeneous tumor. Xenograft tumors derived from EpCAM^high^/CD44^+^ cells consisted of both the EpCAM^high^/CD44^+^ population and the EpCAM^positive^/CD44^−^ population ([Fig. 1C](#f1-or-40-02-0693){ref-type="fig"}). We also examined the histological type of the xenograft tumors. H&E staining of a xenograft tumor revealed abnormal ductal morphogenesis, indicating that it was a moderately differentiated adenocarcinoma, which was the same histological type as the primary human CRC ([Fig. 1D](#f1-or-40-02-0693){ref-type="fig"}). These xenograft tumors therefore histologically were the same as the primary tumors. In addition, the EpCAM^high^/CD44^+^ population from the xenograft tumor could produce tumors that exhibited the same histology as human CRC in serially transplanted mice. Thus, we repeated transplantation four times, and each time, the tumor that developed exhibited the same histology ([Fig. 1E](#f1-or-40-02-0693){ref-type="fig"}). These results indicated that EpCAM^high^/CD44^+^ CRC cells possess the ability to self-renew and produce heterogeneous tumors with the same histology as the primary tumor *in vivo*.

### The EpCAM^high^/CD44^+^ population expresses E-cadherin, but not N-cadherin

E-cadherin is essential for the self-renewal ability of embryonic stem cells ([@b16-or-40-02-0693],[@b21-or-40-02-0693]). In addition, N-cadherin is important to maintain stemness in hematopoietic stem cells ([@b22-or-40-02-0693]). We hypothesized that cadherin superfamily members may play a role in maintaining the stemness of colorectal CSCs. First, we sorted EpCAM^high^/CD44^+^ and EpCAM^positive^/CD44^−^ populations and examined E-cadherin expression in the EpCAM^high^/CD44^+^ population using flow cytometric analysis; 15.8% of these EpCAM^high^/CD44^+^ cells expressed E-cadherin (10.8--20.0%; n=3; [Fig. 2A](#f2-or-40-02-0693){ref-type="fig"}). Immunohistochemical staining indicated that CD44-positive cells in atypical ducts expressed E-cadherin ([Fig. 2B](#f2-or-40-02-0693){ref-type="fig"}, red arrow), but that E-cadherin was downregulated in CD44-positive cells in the tumor invasive area ([Fig. 2B](#f2-or-40-02-0693){ref-type="fig"}, yellow arrow). Since a previous study revealed that cancer cells that had undergone epithelial-mesenchymal transition (EMT) had CSC properties ([@b23-or-40-02-0693]), EC^−^ EpCAM^high^/CD44^+^ cells were hypothesized to express N-cadherin, which is a marker of EMT. We next examined N-cadherin expression in the EpCAM^high^/CD44^+^ cells using flow cytometry. As shown in [Fig. 2C](#f2-or-40-02-0693){ref-type="fig"}, N-cadherin expression was not observed in EpCAM^high^/CD44^+^ cells from primary human tumors (0--0.97%; n=3; [Fig. 2C](#f2-or-40-02-0693){ref-type="fig"}). These results revealed that EpCAM^high^/CD44^+^ cells could be divided into two populations based on E-cadherin expression status and that EMT may not be related to E-cadherin downregulation in EpCAM^high^/CD44^+^ cells in primary human colorectal tumors.

### E-cadherin expressing EpCAM^high^/CD44^+^ cells have higher tumorigenic potential in vivo

To investigate differences in the pathological phenotype between EC^+^ EpCAM^high^/CD44^+^ cells and EC^−^ EpCAM^high^/CD44^+^ cells, we isolated each cell population from human primary colorectal tumors and transplanted the isolated cells subcutaneously into NOD/SCID mice (n=7, patients \#44, 49, 63, 64, 70, 71 and 74). Ten weeks after injection, four out of the eight mice that were injected with more than 3×10^3^ EC^+^ EpCAM^high^/CD44^+^ cells bore tumors. In particular, three of the four tumors originated from patient \#49, and one originated from patient \#63. In contrast, one of the six mice had a xenograft tumor after injection of 3×10^3^ EC^−^ EpCAM^high^/CD44^+^ cells from patient \#63 ([Table II](#tII-or-40-02-0693){ref-type="table"} and [Fig. 3A](#f3-or-40-02-0693){ref-type="fig"}). However, no statistically significant difference was found in terms of tumorigenicity, because only one of the five mice bore a tumor when 3×10^3^ EC^+^ EpCAM^high^/CD44^+^ cells were injected (P=0.297).

Then, we hypothesized that EC^+^ cells from xenograft tumors may have a higher tumorigenic potential *in vivo*. To assess this, we isolated EC^+^ and EC^−^ cells from xenograft tumors that originated from patients \#8, 49, 50 and 62 and injected them into immunodeficient mice. Both EC^+^ and EC^−^ cells from xenograft tumors exhibited higher tumorigenic potential compared to cells from primary tumors. All mice that had been injected with more than 3×10^3^ EC^+^ cells bore tumors. In addition, two of the three mice bore tumors after 1×10^3^ EC^+^ cells were injected. In contrast, five of the seven mice that had been injected with more than 3×10^3^ EC^−^ cells had tumors ([Table II](#tII-or-40-02-0693){ref-type="table"}). We did not detect a significant difference regarding tumorigenicity in this setting (P=0.099).

Although both EC^+^ and EC^−^ cells exhibited tumorigenic potential *in vivo*, EC^+^ cells produced significantly larger and heavier tumors. The average weight of a tumor derived from EC^+^ cells was 5.01 g (1.43--7.94 g, n=5), whereas that derived from EC^−^ cells was 1.64 g (0.00--2.92 g, n=5, P=0.026; [Fig. 3B](#f3-or-40-02-0693){ref-type="fig"}). H&E staining of xenograft tumors derived from EC^+^ or EC^−^ cells revealed that the tumors had the same histology ([Fig. 3C](#f3-or-40-02-0693){ref-type="fig"}). Based on these results, EC^+^ EpCAM^high^/CD44^+^ cells had higher tumor growth potential *in vivo* compared to EC^−^ EpCAM^high^/CD44^+^ cells.

### cDNA microarray identifies genes potentially related to the higher tumor growth ability of EC^+^ EpCAM^high^/CD44^+^ cells

To explore the genetic profile leading to the difference in tumor growth potential between EC^+^ and EC^−^ EpCAM^high^/CD44^+^ cells, we isolated 5×103 EC^+^ and EC^−^ EpCAM^high^/CD44^+^ cells from primary tumors of patients \#24, 180, 182, 187, and 211, and analyzed the mRNA expression of 41,628 genes using a cDNA microarray (Agilent Technologies, Santa Clara, CA, USA). Different gene expression profiles were obtained for the EC^+^ and EC^−^ EpCAM^high^/CD44^+^ cells ([Fig. 4A](#f4-or-40-02-0693){ref-type="fig"}). We subsequently focused on NANOG expression since NANOG is a transcription factor that is essential for self-renewal and pluripotency of embryonic stem cells. Moreover, NANOG has been revealed to be associated with increased cell proliferation in the colon ([@b24-or-40-02-0693]). In four out of five populations of EC^+^ cells, NANOG expression was upregulated more than four times, compared to EC^−^ cells. The expression of CDX2, which is a crypt-like differentiation marker, was not upregulated in EC^−^ cells ([Fig. 4B](#f4-or-40-02-0693){ref-type="fig"}, [Table III](#tIII-or-40-02-0693){ref-type="table"}). We then compared the expression of EMT-related genes between EC^+^ cells and EC^−^ cells. Consistent with previous data, EMT-related gene expression was not different between the cell types, and the CDH1 mRNA level was not altered ([Fig. 4C](#f4-or-40-02-0693){ref-type="fig"}, [Table III](#tIII-or-40-02-0693){ref-type="table"}). Next, we confirmed the expression of NANOG in EpCAM^high^/CD44^+^ cells using immunofluorescence. NANOG expression was detected in the nucleus of one of eight EC^+^ EpCAM^high^/CD44^+^ cells ([Fig. 4D](#f4-or-40-02-0693){ref-type="fig"}).

These results revealed that NANOG may be involved in the higher tumor growth ability of EC^+^ CSC cells, but was not associated with CSC properties or EMT in colorectal CSCs.

### NANOG increases CSC proliferation through cyclin D1 expression

To confirm that NANOG-induced higher cell proliferation ability in EC^+^ colorectal CSCs, we knocked out NANOG expression in the HCT116 CRC cell line with siRNA, since this cell line expresses CD44, a colorectal CSC marker, and NANOG. As expected, *NANOG* siRNA-transfected cells demonstrated lower cell proliferation ability than control siRNA-transfected cells ([Fig. 5A](#f5-or-40-02-0693){ref-type="fig"}). To confirm the knockout of *NANOG*, we estimated *NANOG* mRNA levels with RT-qPCR 4 days after transfection. Compared to the control siRNA-transfected cells, the *NANOG* mRNA level was significantly decreased in *NANOG* siRNA-transfected cells ([Fig. 5B](#f5-or-40-02-0693){ref-type="fig"}). In addition, our RT-PCR analysis also revealed downregulation of *NANOG* mRNA expression ([Fig. 5C](#f5-or-40-02-0693){ref-type="fig"}).

We performed an immunofluorescence study to confirm NANOG protein downregulation. All control HCT116 cells expressed NANOG protein in the nucleus, and we could not detect NANOG protein in some siRNA-transfected cells 4 days after transfection ([Fig. 5D](#f5-or-40-02-0693){ref-type="fig"}).

Next, we analyzed the mechanism of the decreased proliferation ability induced by downregulation of NANOG. Since NANOG regulates cell cycle-related gene expression ([@b25-or-40-02-0693],[@b26-or-40-02-0693]), we hypothesized that the lower cell proliferation ability may be due to cyclin D1 downregulation after knockout of NANOG. We analyzed mRNA expression of cell cycle-related genes 4 days after siRNA transfection. RT-PCR data revealed that *cyclin D1* mRNA levels were decreased in *NANOG* siRNA-transfected cells. In addition, *cyclin B1* mRNA levels were also decreased, especially in one siRNA-transfected cell line, but mRNA levels of other cyclins, p21, and p27 were not altered ([Fig. 5E](#f5-or-40-02-0693){ref-type="fig"}).

These data revealed that NANOG increased CRC cell proliferation through up-regulation of cyclin D1, and that cyclin B1 may also be involved in this process. In particular, NANOG controlled colorectal CSC proliferation, leading to the difference in the tumor growth rate between EC^+^ CSCs and EC^−^ CSCs ([Fig. 6](#f6-or-40-02-0693){ref-type="fig"}).

Discussion
==========

The classical understanding of the concept of CSCs is that tumor tissue arises from CSCs and that a limited population of tumor cells during tumor growth has CSC properties. The CSC population is considered to be uniform because it is small in numbers. However, cancer cells that undergo EMT also possess CSC properties ([@b23-or-40-02-0693]), and this EMT-induced stemness is possibly important for development of metastatic cancer lesions. According to this concept, the CSC population is thought to consist of heterogeneous cells. However, whether heterogeneous CSCs exist in the primary tumor is unclear.

We identified two different populations of CSCs in the primary tumor based on E-cadherin expression status for the first time. E-cadherin-expressing CSCs (EC^+^ CSCs) and E-cadherin-deficient CSCs (EC^−^ CSCs) existed within the EpCAM^high^/CD44^+^ colorectal CSC population. Expression of *CDH1*, which encodes the E-cadherin protein, is downregulated by several EMT-related genes such as *SNAIL, TWIST* and *SLUG*. However, the cDNA array analysis of the present study revealed no differences in the expression of *CDH1* or EMT-related genes between EC^+^ CSCs and EC^−^ CSCs. In addition, expression of N-cadherin, which is believed to be highly expressed in cells during the EMT process, was not detected in EC^−^ CSCs, either by flow cytometry or immunohistochemical staining. Our data revealed that the downregulation of E-cadherin expression that we observed does not represent a step in the EMT process and that distinct expression levels of E-cadherin in each CSC population may be regulated by signals other than EMT programs, such as SRC, epidermal growth factor, and WNT ([@b27-or-40-02-0693],[@b28-or-40-02-0693]). Thus, our data indicated that human primary CRC tissue contains CSCs that consist of EC^+^ CSCs and EC^−^ CSCs, and suggest that differences between these two CSC phenotypes are independent of the EMT process.

EC^+^ CSCs and EC^−^ CSCs demonstrated pathologically different phenotypes. Although both EC^+^ CSCs and EC^−^ CSCs had self-renewal ability and produced tumors with the same histology in immunodeficient mice, EC^+^ CSCs from primary tumors exhibited higher tumor growth potential than EC^−^ CSCs from primary tumors *in vivo* This observation strongly suggested that signal transduction-promoting cell growth was enhanced in EC^+^ CSCs compared to EC^−^ CSCs. Such a higher growth ability of EC^+^ CSCs is possibly due to the increased expression of NANOG. NANOG is a key transcription factor that maintains the pluripotency of human embryonic stem cells by blocking differentiation and establishing the pluripotent ground state during somatic cell reprogramming ([@b29-or-40-02-0693]). NANOG expression has been reported in human tumors, especially in CSCs of prostate cancer, ovarian cancer and CRC ([@b30-or-40-02-0693]--[@b32-or-40-02-0693]). We had previously revealed that NANOGP8 was overexpressed in the human colorectal CSC population and that downregulation of NANOG by siRNA reduced cellular proliferation ([@b33-or-40-02-0693]). Therefore, the higher growth ability of EC^+^ CSCs could be understood in terms of their association with preferential NANOG expression. In the present study, we demonstrated that downregulation of *NANOG* by siRNA reduced cyclin D1 expression, and this may be the main explanation for the lower proliferation ability of EC^−^ CSCs. In this aspect, we considered EC^+^ CSCs to be proliferating CSCs and EC^−^ CSCs to be quiescent CSCs.

Many transcription factors have been identified in human embryonic stem cells that are recruited to the NANOG locus to regulate its expression ([@b29-or-40-02-0693]). Although direct interactions between the E-cadherin/β-catenin signaling pathway and increased NANOG expression still remain unclear in human colorectal CSCs, Hawkins *et al* reported that E-cadherin promoted Nanog transcript and protein expression in mouse embryonic stem cells. In their study, they revealed that Stat3 signaling was involved in Nanog expression and that the β-catenin binding site region in E-cadherin was essential ([@b34-or-40-02-0693]). The same results were reported by Valle *et al* ([@b35-or-40-02-0693]). In addition, it was revealed that STAT3 promoted stemness in CRC ([@b36-or-40-02-0693],[@b37-or-40-02-0693]). With these results, STAT3 signaling may also be involved in NANOG expression by E-cadherin in human colorectal CSCs.

The present study is the first to demonstrate that the EpCAM^high^/CD44^+^ colorectal CSC population consists of heterogeneous populations, such as EC^+^ CSCs and EC^−^ CSCs. Although both populations possess stem cell properties, which could reconstitute tumors consisting of both populations in human CRC tissues, they exhibited pathologically different phenotypes. EC^+^ CSCs exhibited higher proliferative potential, possibly due to high NANOG expression, leading to increased cyclin D1 and cyclin B1 expression. On the other hand, EC^−^ CSCs are thought to be in a more quiescent state than EC^+^ CSCs due to the low expression of cyclin D1. E-cadherin downregulation in EC^−^ CSCs was independent of the EMT process, and EC^−^ CSCs have the ability to revert to EC^+^ CSCs depending on their environment.
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![Tumorigenic potential of EpCAM^high^/CD44^+^ colorectal cancer cells *in vivo*. (A) Flow cytometric analysis of a human colorectal cancer. A small EpCAM^high^/CD44^+^ population was detected in the human colorectal cancer. (B) Only EpCAM^high^/CD44^+^ cells had tumorigenic potential in NOD/SCID mice. (C) Flow cytometric analysis of a xenograft tumor. EpCAM^high^/CD44^+^ cells gave rise to EpCAM^positive^/CD44^−^ cells and reconstituted the expression profiles of the primary sample. (D) H&E staining of a primary and a xenograft tumor. The histology of the xenograft tumor was the same as that of the primary tumor. (E) Serial transplantation recapitulated the histology of the primary tumors.](OR-40-02-0693-g00){#f1-or-40-02-0693}

![E-cadherin expression in EpCAM^high^/CD44^+^ colorectal cancer cells. (A) EpCAM^high^/CD44^+^ colorectal cancer cells contained an E-cadherin^+^ and an E-cadherin^−^ population. (B) Immunohistochemical staining of a human colorectal cancer specimen. The red arrow indicates CD44 (black) and E-cadherin (green) double-positive cells. The yellow arrow indicates CD44 (black) positive but E-cadherin negative cells. (C) N-cadherin was not expressed in EpCAM^high^/CD44^+^ colorectal cancer cells.](OR-40-02-0693-g01){#f2-or-40-02-0693}

![Higher tumorigenic potential of E-cadherin^+^ colorectal CSCs. (A) Image of a mouse bearing a xenograft tumor from EC^+^ and EC^−^ colorectal CSCs and flow cytometric analyses of their phenotype. (B) Tumor weight of xenograft tumors. Error bars represent the 95% confidence interval. EC^+^ colorectal CSCs produced significantly larger tumors compared to EC^−^ colorectal CSCs. \*P\<0.01 (C) Histopathological analysis of xenograft tumors from EC^+^ CSCs and EC^−^ CSCs.](OR-40-02-0693-g02){#f3-or-40-02-0693}

![Upregulation of *NANOG* expression in EC^+^ CSCs. cDNA microanalysis of (A) total gene expression, (B) transcription-related (including *NANOG*) gene expression, and (C) EMT-related gene expression in EC^+^ and EC^−^ CSCs. (A) Total gene expression differed between EC^+^ CSCs and EC^−^ CSCs. (B) *NANOG* expression was significantly upregulated in EC^+^ CSCs vs. EC^−^ CSCs. (C) Expression of genes related to EMT did not differ between EC^+^ CSCs and EC^−^ CSCs. (D) Immunofluorescence staining of a human colorectal cancer specimen. NANOG was expressed in the nucleus of CD44 and E-cadherin double-positive colorectal cancer cells (yellow arrow).](OR-40-02-0693-g03){#f4-or-40-02-0693}

![NANOG regulates colorectal cancer cell proliferation through the control of cyclin D1 expression. (A) Growth curve of HCT116 colorectal cancer cells. *NANOG* siRNA-transfected cells exhibited decreased cell proliferation compared to the control. (B) Quantitative RT-PCR (\*P\<0.01) and (C) RT-PCR identified *NANOG* suppression in siRNA-transfected cells. (D) An immunofluorescence study revealed the downregulation of NANOG protein after siRNA transfection. (E) RT-PCR for cyclins. Cyclin D1 and cyclin B1 mRNA levels were decreased in siRNA-transfected cells, but the expression levels of other cyclins, p21, and p27 were not changed.](OR-40-02-0693-g04){#f5-or-40-02-0693}

![The concept of this study. The CSC population is a heterogeneous population that contains EC^+^ and EC^−^ cells. Although both EC^+^ cells and EC^−^ cells have the ability to produce a tumor in immunodeficient mice, EC^+^ colorectal CSCs have higher tumor growth ability. E-cadherin and NANOG may regulate colorectal CSC proliferation through the control of cyclin D1 expression.](OR-40-02-0693-g05){#f6-or-40-02-0693}

###### 

Patient characteristics.

  No.      Age   Sex   Primary site   Histology     Stage^[a](#tfn1-or-40-02-0693){ref-type="table-fn"}^
  -------- ----- ----- -------------- ------------- ------------------------------------------------------
    \#6    42    M     R              Mod           IIIA
    \#7    51    M     T              Well to mod   I
    \#8    83    M     A              Mod to poor   IVA
    \#24   77    M     R              Well          IIA
    \#44   43    F     R              Mod           IIA
    \#49   60    M     T              Mod           IIA
    \#50   72    F     C              Poor          IIB
    \#58   78    F     S              Mod           IIA
    \#62   77    F     A              Well          IVA
    \#63   43    F     A              Well to mod   IIIC
    \#64   74    M     A              Well to mod   IIA
    \#70   58    M     S              Well          IIA
    \#71   63    F     R              Well to mod   IIA
    \#74   72    F     D              Mod           IIA
  \#180    72    M     A              Well to Mod   IIIB
  \#182    61    F     C              Well          IIIB
  \#187    73    F     C              Poor          IIIC
  \#211    63    M     R              Well          IIIC

UICC TNM classification. M, male; F, female; C, cecum; A, ascending colon; T, transverse colon; D, descending colon; R, rectum; Well, well-differentiated adenocarcinoma; Mod, moderately differentiated adenocarcinoma; Poor, poorly differentiated adenocarcinoma.

###### 

Tumor-initiating potential of E-Cadherin^+^ and ^−^ cells within the EpCAM^high^/CD44^+^ population *in vivo*.

                                    Injected EC^+^ or EC^−^ EpCAM^high^/CD44^+^ cell number (from the primary sample)                                                              
  --------------------------------- ---------------------------------------------------------------------------------------- ---------- ---------- ---------- ---------- --------- -------------
  E-cadherin^+^                     3/3                                                                                      1/5        0/3        --         0/2          0/1     0.297
  E-cadherin^−^                     --                                                                                       1/6        --         0/2        --         --        
  (tumor bearing mice/total mice)                                                                                                                                                  
                                                                                                                                                                                   
                                    **Injected EC^+^ or EC^−^ EpCAM^high^/CD44^+^ cell number (from the xenograft tumor)**                                                         
                                                                                                                                                                                   
                                    **5000**                                                                                 **4000**   **3000**   **2000**   **1000**   **100**   **P-value**
                                                                                                                                                                                   
  E-cadherin^+^                     --                                                                                       1/1        6/6        0/1        2/3          0/1     0.099
  E-cadherin^−^                     1/3                                                                                      1/1        3/3        1/1        1/1        --        
  (tumor bearing mice/total mice)                                                                                                                                                  

###### 

The relative ratio of mRNA expression of stemness and EMT-related genes between EC^+^ and EC^−^ cells (EC^+^/EC^−^).

  A, Transcription-related gene expression                                                                   
  ------------------------------------------ --------------- --------------- --------------- --------------- --------------
  POU5F1                                     0.349898        0.904157        1.078143        3.702691        NULL
  NANOG                                      4.328553        4.141721        1.860814        21.28952        9.054102
  SOX2                                       0.562313        1.136609        1.654131        14.43825        NULL
  SOX6                                       2.599258        2.951994        4.416502        23.84684        0.202682
  KLF4                                       1.024759        1.106549        0.699897        0.709549        0.464341
  BMP7                                       0.453347        0.583328        0.563205        NULL            NULL
  CDX2                                       0.270185        1.509952        0.248415        1.154388        0.536948
                                                                                                             
  **B, EMT-related gene expression**                                                                         
                                                                                                             
                                             \#180 (ratio)   \#182 (ratio)   \#187 (ratio)   \#211 (ratio)   \#24 (ratio)
  CDH1                                       0.959147        0.904071        1.285291        1.474868        0.747187
  CDH2                                       NULL            1.330456        7.381092        0.046765        NULL
  SNAI1                                      1.326144        0.513009        0.849582        0.241307        1.678008
  SNAI2                                      1.325459        2.02312         0.837368        1.275875        1.118609
  TWIST1                                     NULL            NULL            NULL            NULL            NULL
